Articles tagged "Kidney transplantation"

2019 American Transplant Congress
Variations in Recipient and Donor Clinical Characteristics between Kidney Transplant Centers
W. T. McKinney¹, M. Bruin², S. Chu², D. Schladt³, J. Snyder³, A. Matas⁴, B. Kasiske⁵, A. K. Israni³
¹Nephrology, Hennepin Healthcare Research Institute, Minneapolis, MN, ²College of Design, University of Minnesota, St. Paul, MN, ³Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN, ⁴Department of Surgery, University of Minnesota, Minneapolis, MN, ⁵Department of Medicine, Hennepin Healthcare, Minneapolis, MN
*Purpose: When a patient can choose at which kidney transplant program to establish care, prior knowledge of program acceptance practices (of candidates and donors) can…
2019 American Transplant Congress
Impact of Everolimus Therapy on HIV Persistence and Gene Expression in Transplant Patients
A. Zarinsefat¹, C. Schreiner¹, C. Cameron², S. Chu¹, M. P. Busch¹, T. Liegler¹, S. G. Deeks¹, T. J. Henrich¹, P. G. Stock¹
¹UC San Francisco, San Francisco, CA, ²Case Western Reserve University, Cleveland, OH
*Purpose: mTOR is a key regulatory kinase that controls cell-cycle progression. mTOR inhibitors have been shown to reduce expression of CCR5 and promote viral transcriptional…
2019 American Transplant Congress
Impact of an mHealth, Electronic Pillbox Intervention on Tacrolimus Variability in Kidney Transplantation: Results of a Prospective Randomized Clinical Trial
J. W. McGillicuddy, L. Sox, J. Chandler, F. Treiber, D. Taber
Medical University of South Carolina, Charleston, SC
*Purpose: Medication non-adherence (MNA) is a major risk factor and leading cause of late allograft loss in kidney transplant (KTX) recipients. Tacrolimus trough concentration variability,…
2019 American Transplant Congress
Blood Profiling Reflects a Significant Down-Regulation in Oxidative Phosphorylation Following Renal Transplantation with DCD and AKI Allografts
S. Walker¹, L. Cox², C. Langefeld², B. Freedman², A. Farney², J. Rogers², C. Jay², R. Stratta², G. Orlando²
¹Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, ²Wake Forest Baptist Medical Center, Winston Salem, NC
*Purpose: The human kidney transplant (KT) patient provides a unique and compelling in situ model system to study molecular events that underlie graft recovery following…
2018 American Transplant Congress
Ischemia Reperfusion Injury & Risk for Antibody Mediated Rejection (ABMR) in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH)
A. Vo,¹ O. Aubert,² J. Choi,¹ N. Ammerman,¹ H. Edmund,¹ A. Peng,¹ R. Najjar,¹ S. Supreet,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Paris Translational Research for Organ Transplantation, Necker Hospital, Paris, France.
Introduction: Ischemia reperfusion injury (IRI) contributes to delayed graft function (DGF). IRI/DGF in HLA-sensitized (HS) patients likely activates innate and memory injury pathways that may…
2018 American Transplant Congress
Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study
S. Mulgaonkar,¹ Y. Qazi,¹ D. Kim,¹ V. Peddi,¹ K. McCague,² D. Patel,² A. Wiseman.¹
¹TRANSFORM Study Group, Livingston; ²Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…
2018 American Transplant Congress
Molecular Profiling of the Injury-Repair Response in Early Subclinical Inflammation
M. Seifert, D. Della Manna, X. Liu, F. Rosenblum, M. Yanik, E. Yang, J. Pollock, R. Mannon.
UAB School of Medicine, Birmingham.
Purpose: Surveillance biopsies can detect subclinical T-cell mediated rejection (SC-TCMR) or subclinical borderline rejection (SC-B-TCMR) in kidney transplants with normal/stable creatinine. Some consider SC-B-TCMR to…
2018 American Transplant Congress
Belatacept Maintenance Immunosuppression Use and Outcomes in the Real-World Clinical Setting Using OPTN/UNOS Kidney Transplant Registry
S. Sanoff,¹ K. Ravindra,¹ W. Irish.^1,2
¹Duke University Medical Center, Durham, NC; ²CTI Consulting, Raleigh, NC.
Introduction:Belatacept (BEL) was FDA approved for Kidney Transplantation (KTx) June 2011. It has largely been evaluated in two controlled trials (N Engl J Med 2016;374:333-43).…
2018 American Transplant Congress
Evolving Etiologies for Readmissions and Their Impact on Graft Survival in Kidney Transplantation
D. Taber, N. Pilch, Z. Su, C. Mardis, J. Fleming, N. Patel, H. Meadows, P. Mauldin, V. Rao, D. Dubay.
MUSC, Charleston, SC.
Background: Although readmissions after kidney transplant are a well-known risk factor for graft loss, it is unclear if certain etiologies are associated with poorer outcomes…
2018 American Transplant Congress
Kidney Transplant Allocation with CMV Seromatching Reduces CMV Infection without Affecting Wait Times
A. Narra,¹ L. Strasfeld,² D. Basuli,¹ M. Stack,¹ E. Langewisch,³ A. Olyaei,¹ D. Norman,^1,4 J. Lockridge.^1,4
¹Transplant Nephrology, Oregon Health and Science University, Portland, OR; ²Infectious Diseases, OHSU, Portland, OR; ³Transplant Nephrology, University of Nebraska Medical Center, Omaha, NE; ⁴Transplant Nephrology, Portland VA, Portland, OR.
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in kidney transplant recipients.A pre-transplant allocation strategy by matching deceased kidney donors and recipients…